Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Manolya Saydam"'
Autor:
Mohamed Deifallah Yousif, Arif Felek, Manolya Saydam, Seanette Wilson, Sudaxshina Murdan, Fatme Mawas
Publikováno v:
Vaccine. 40(42)
No vaccines are currently licensed against Group B streptococcus (GBS), an important cause of morbidity and mortality in babies and adults. Using a mouse model, and in vitro opsonophagocytosis and colonisation assays, we evaluated the potential of a
Publikováno v:
Biologicals. 42:29-33
Current Haemophilus influenzae b conjugate vaccines (Hib), which are made of purified capsular polysaccharide (poly-ribosyl-ribitol-phosphate; PRP) conjugated to a carrier protein, are almost completely evaluated by physico-chemical methods to ensure
Autor:
Fatme Mawas, Manolya Saydam, Woei Ping Cheng, Rob Tierney, Robert J. Francis, Ambreen Khan, Kirsty MacLellan-Gibson, Nathan Palmer
Publikováno v:
Vaccine. 35(18)
The use of Soluplus® polymeric micelles as a novel adjuvant for tetanus toxoid (TTxd) in transcutaneous immunisation was evaluated. TTxd was added to Soluplus® polymeric micelles to form TTxd-Soluplus® nano-aggregates with a size of 68 nm. Non-adj
Publikováno v:
Vaccine. 29:3213-3221
The immunogenicity and physico-chemical characteristics of a candidate conjugate vaccine against group B streptococcus serotypes Ia, Ib and III, were evaluated. The level and functional activity of serotype-specific antibody responses induced by mono
Autor:
Fatme, Mawas, Karena, Burkin, Thomas, Dougall, Manolya, Saydam, Peter, Rigsby, Barbara, Bolgiano, C Rama, Krishna
Publikováno v:
Biologicals : journal of the International Association of Biological Standardization. 43(6)
In this report we present the results of a collaborative study for the preparation and calibration of a replacement International Standard (IS) for Haemophilus influenzae type b polysaccharide (polyribosyl ribitol phosphate; 5-d-ribitol-(1 → 1)-β-
Autor:
Barbara Bolgiano, Dennis T. Crane, Michael J. Corbel, Karena Burkin, Fatme Mawas, Peter Rigsby, Manolya Saydam
Publikováno v:
Human vaccines. 3(5)
Following the reduction in efficacy of Hib-TT vaccines in the primary immunization schedule observed in the UK between 1999 and 2003, batches of vaccine manufactured by two different companies were retrospectively examined by the National Institute f
Publikováno v:
Vaccine. 25(25)
The physico-chemical characteristics and immunogenicity of a candidate vaccine against otitis media, prepared from recombinant lipidated outer membrane proteins (rLP4 and rLP6) from non-typeable Haemophilus influenzae (NTHi) and of the ubiquitous cel